Copy Number Profiling of MammaPrint Genes Reveals Association with the Prognosis of Breast Cancer Patients
PUBLICATION: J Breast Cancer. 2017 Sep;20(3):246-253. English. Published online Sep Read More
Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor–Positive Early Breast Cancer: Results of a Prospective Cohort Study GalleryImpact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor–Positive Early Breast Cancer: Results of a Prospective Cohort Study
Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor–Positive Early Breast Cancer: Results of a Prospective Cohort Study
PUBLICATION: Journal of Clinical Oncology 35, no. 24 (August 20, Read More
- Characterisation of Multifocal Breast Cancer Using the 70-gene Signature in Clinical Low-Risk Patients Enrolled in the EORTC 10041/BIG 03-04 MINDACT Trial. Gallery
Characterisation of Multifocal Breast Cancer Using the 70-gene Signature in Clinical Low-Risk Patients Enrolled in the EORTC 10041/BIG 03-04 MINDACT Trial.
Characterisation of Multifocal Breast Cancer Using the 70-gene Signature in Clinical Low-Risk Patients Enrolled in the EORTC 10041/BIG 03-04 MINDACT Trial.
PUBLICATION: European Journal of Cancer. July 2017, Volume 79, Pages Read More
A Breast Cancer Gene Signature for Indolent Disease
PUBLICATION: Breast Cancer Res Treat. 2017 Oct;117(3):483-95. doi: 10.1007/s10549-008-0191-2. Epub Read More
Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) GalleryPertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)
Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)
PUBLICATION: Ann Surg Oncol. 2017 Sep;24(9):2539-2546. doi: 10.1245/s10434-017-5863-x. AUTHORS: Peter Read More
- DNA Repair Deficiency Biomarkers and the 70-Gene Ultra-High Risk Signature as Predictors of Veliparib/Carboplatin Response in the I-SPY 2 Breast Cancer Trial Gallery
DNA Repair Deficiency Biomarkers and the 70-Gene Ultra-High Risk Signature as Predictors of Veliparib/Carboplatin Response in the I-SPY 2 Breast Cancer Trial
DNA Repair Deficiency Biomarkers and the 70-Gene Ultra-High Risk Signature as Predictors of Veliparib/Carboplatin Response in the I-SPY 2 Breast Cancer Trial
PUBLICATION: NPJ Breast Cancer. 2017 Aug 25;3:31. doi: 10.1038/s41523-017-0025-7. AUTHORS: Read More
Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer
PUBLICATION: Biomark Insights. 2016; 11: 139–146. doi: 10.4137/BMI.S38435 AUTHORS: Inès Read More
- Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping Gallery
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping
PUBLICATION: Annals of Surgical Oncology; March 2017, Volume 24, Issue Read More
Genomic Profiling of Breast Cancer in African-American Women Using MammaPrint.
PUBLICATION: Breast Cancer Res Treat (2016) 159: 481. https://doi.org/10.1007/s10549-016-3949-y09. AUTHORS: Read More
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
PUBLICATION: N Engl J Med 2016; 375:717-729; DOI: 10.1056/NEJMoa1602253. AUTHORS: Read More
